Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data

Journey Medical Corp (NASDAQ:DERM) is one of the best performing micro cap stocks in 2025. On January 4, Lake Street analyst Thomas Flaten reaffirmed a Buy rating on Journey Medical Corp (NASDAQ:DERM) with a $13 price target.

Earlier on December 10, Journey Medical Corp published results from a Phase 1 clinical trial, focusing on Emrosi’s impact on microbial flora in healthy adults, in the Journal of Drugs in Dermatology. Emrosi is an FDA-approved oral medication used to treat skin conditions such as papules and pustules in adults.

According to Journey Medical, the trial met all three primary endpoints. That is, there were no significant microbiome changes in skin; no notable antibiotic resistance to minocycline; and no major rise in opportunistic organisms compared to placebo. The data showed that Emrosi is well tolerated with no significant safety concerns. This aligns with its low-dose profile to minimize disruption to normal body flora and support safe, extended use in rosacea patients, Journey Medical noted.

Claude Maraoui, Journey Medical’s co-founder, president, and CEO, noted that this publication reinforces Emrosi’s differentiated benefits as a low-dose option that avoids meaningful microbial disruption or resistance, based on consistent data across trials.

Emrosi received FDA approval in November 2024. This made it the only oral therapy approved for addressing both inflammatory lesions and redness in rosacea. The approval was supported by two Phase 3 clinical trials, MVOR-1 and MVOR-2, conducted from March 2022 to May 2023 in the US and Germany.

Journey Medical Corp (NASDAQ:DERM) is a commercial-stage pharmaceutical company focused on developing and marketing prescription dermatology products. Its portfolio includes treatments for conditions such as acne, rosacea, actinic keratosis, and fungal infections.

While we acknowledge the potential of DERM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Must-Buy AI Stocks to Invest In and 11 Best NYSE Stocks Under $5 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.